{
    "clinical_study": {
        "@rank": "161346", 
        "arm_group": [
            {
                "arm_group_label": "NCC2461", 
                "arm_group_type": "Active Comparator", 
                "description": "probiotic blended in maltodextrin powder to be taken daily"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "maltodextrin"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy of a probiotic strain in improving the\n      quality of life in adult subjects suffering from perennial allergic rhinit."
        }, 
        "brief_title": "Probiotic Administration and Perennial Allergic Rhinitis", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Rhinitis, Allergic, Perennial", 
        "condition_browse": {
            "mesh_term": [
                "Rhinitis", 
                "Rhinitis, Allergic, Perennial"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults between 20-65 years old\n\n          -  Confirmed allergy (allergic rhinitis) to dust mite for more than 2 years, as\n             determined by anamnesis and by a  miniRQLQ of \u2265 1\n\n          -  Positive Skin prick testing measure greater than 3mm wheal diameter to the\n             dermatophagoides pteronyssinus species of house dust mite extract\n\n          -  Body Mass Index 19-29\n\n          -  Having obtained his/her informed consent\n\n        Exclusion Criteria:\n\n          -  Anemia\n\n          -  Allergy to any food or medication\n\n          -  Asthma\n\n          -  Family history of congenital immunodeficiency or chronic consumption (more than one\n             week at Screening) of immunosuppressive or anti-inflammatory treatments\n\n          -  Ongoing treatment with antibiotics or undergoing allergen immunotherapy at Screening\n\n          -  Consumption of probiotic and other dietary nutritional interventions\n\n          -  More than 2 drinks/day alcohol consumption or use of illicit drugs\n\n          -  Pregnant women\n\n          -  Subjects with expected low compliance\n\n          -  Blood donation in the past month or planning to donate blood until a month after the\n             end of the study\n\n          -  Currently participating or having participated in another interventional clinical\n             trial during the last four weeks prior to the beginning the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01779895", 
            "org_study_id": "12.18.MET"
        }, 
        "intervention": [
            {
                "arm_group_label": "NCC2461", 
                "intervention_name": "Lactobacillus paracasei probiotic strain", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "maltodextrin", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Dust mite", 
            "Perennial allergic rhinitis"
        ], 
        "lastchanged_date": "April 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lausanne", 
                    "country": "Switzerland", 
                    "zip": "1000"
                }, 
                "name": "Metabolic Unit, Nestl\u00e9 Research Centre"
            }
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Probiotic Lactobacillus Paracasei NCC2461 on House Dust Mite Allergy", 
        "overall_official": {
            "affiliation": "Nestl\u00e9 Research Centre", 
            "last_name": "Maurice Beaumont, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Compared over 8 weeks between the two treatment groups", 
            "measure": "Quality of life, measured by a validated mini rhinoconjunctivitis quality of life questionnaire (MiniRQLQ)", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01779895"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Level of pro-inflammatory cytokines in ex-vivo stimulated whole blood cells", 
                "safety_issue": "No", 
                "time_frame": "Measured 3 times: at the start of product intake, after 4 weeks and after 8 weeks"
            }, 
            {
                "measure": "Basophil activation in ex-vivo stimulated whole blood cells", 
                "safety_issue": "No", 
                "time_frame": "Measured 3 times: at the start of product intake, after 4 weeks and after 8 weeks"
            }, 
            {
                "measure": "Total Nasal Symptom Score (TNSS), Total Ocular Symptom Score (TOSS), Medication score", 
                "safety_issue": "No", 
                "time_frame": "Measured weekly for the 8 weeks of product intake"
            }, 
            {
                "measure": "Level of Specific Immunoglobulin E", 
                "safety_issue": "No", 
                "time_frame": "Measured 2 times: at the start of product intake and after 8 weeks"
            }, 
            {
                "measure": "Frequency of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "during the 8 weeks of product intake"
            }
        ], 
        "source": "Nestl\u00e9", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nestl\u00e9", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}